Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Biohaven Ltd. made materially false and/or misleading statements and/or failed to disclose that:
Biohaven issued a press release on May 14, 2025, "announc[ing] that the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the PDUFA date for the troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA." The press release further stated that "[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled."
Following this news, Biohaven's stock price fell over 19% on May 15, 2025.
In order to be eligible to join the BHVN class action lawsuit, you must have incurred a loss on shares of Biohaven Ltd. purchased during the class period listed above.
TOP
